Literature DB >> 18566394

Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis.

Jenny Jongstra-Bilen1, Adrianet Puig Cano, Manvi Hasija, Haiyan Xiao, C I Edvard Smith, Myron I Cybulsky.   

Abstract

Tec family nonreceptor tyrosine kinases are expressed by hematopoietic cells, activate phospholipase C (PLC)gamma, and regulate cytoskeletal rearrangement, yet their role in FcgammaR-induced signaling and phagocytosis remains unknown. We demonstrate in this study that Bruton's tyrosine kinase (Btk) and Tec, the only Tec kinases expressed by RAW 264.7 cells, are activated throughout phagocytosis. Activated Btk and Tec kinase accumulate at an early stage at the base of phagocytic cups and inhibition of their activity by the specific inhibitor LFM-A13 or expression by small interfering RNA significantly inhibited FcgammaR-induced phagocytosis. Similarly, a significant role for these kinases in phagocytosis was found in primary macrophages. FcgammaR-induced activation of Mac-1, which is required for optimal phagocytosis, was markedly inhibited and our findings suggest that the roles of kinases Btk and Tec in Mac-1 activation account for their functions in the early stages of phagocytosis. Initial activation of PLCgamma2, the predominant PLC isoform in RAW 264.7 cells, is dependent on Syk. In contrast, a late and prolonged activation of PLCgamma2 was dependent on Btk and Tec. We found accumulation of diacylglycerol (DAG), a PLCgamma product, in phagosome membranes, and activated Btk, but not Tec, colocalized with phagosomal DAG. Inhibition of Tec family kinase activity increased the level of DAG in phagosomes, suggesting a negative regulatory role for Btk. Tec, in contrast, clustered at sites near phagosome formation. In summary, we elucidated that Tec family kinases participate in at least two stages of FcgammaR-mediated phagocytosis: activation of Mac-1 during ingestion, and after phagosome formation, during which Btk and Tec potentially have distinct roles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566394     DOI: 10.4049/jimmunol.181.1.288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 2.  Novel Treatments in Lupus.

Authors:  Vasileios C Kyttaris
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

3.  SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  J Orthop Res       Date:  2010-11       Impact factor: 3.494

Review 4.  Regulation of tyrosine phosphorylation in macrophage phagocytosis and chemotaxis.

Authors:  Haein Park; Dan Ishihara; Dianne Cox
Journal:  Arch Biochem Biophys       Date:  2011-02-26       Impact factor: 4.013

5.  Bruton's tyrosine kinase mediates FcγRIIa/Toll-like receptor-4 receptor crosstalk in human neutrophils.

Authors:  Agnieszka Krupa; Rafal Fudala; Jon M Florence; Torry Tucker; Timothy C Allen; Theodore J Standiford; Rafal Luchowski; Marek Fol; Moshiur Rahman; Zygmunt Gryczynski; Ignacy Gryczynski; Anna K Kurdowska
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-13       Impact factor: 6.914

6.  NADPH oxidase 2 inhibitor diphenyleneiodonium enhances ROS-independent bacterial phagocytosis in murine macrophages via activation of the calcium-mediated p38 MAPK signaling pathway.

Authors:  Yuanfeng Zhu; Shijun Fan; Ning Wang; Xiaoli Chen; Yongjun Yang; Yongling Lu; Qian Chen; Jiang Zheng; Xin Liu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 7.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

8.  Bruton Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model.

Authors:  Tiziana Palumbo; Kojiro Nakamura; Charles Lassman; Yoko Kidani; Steven J Bensinger; Ronald Busuttil; Jerzy Kupiec-Weglinski; Ali Zarrinpar
Journal:  Transplantation       Date:  2017-02       Impact factor: 4.939

9.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

10.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.